Category: Hansen Medical Inc.
Here's a look at some of the top personnel stories for medical device companies this week.
Hansen Medical lets CEO Bruce Barclay go after the surgical robot maker reports a slide to losses during the 4th quarter.
Hansen Medical (NSDQ:HNSN) is looking for a new CEO to replace Bruce Barclay, who was let go after the robotic surgery company reported a slide to red ink for the 4th quarter.
Hansen Medical's stock rises 20% on FDA clearance for its smaller-diameter Magellan 6Fr catheter and the mandatory exercise of $14 million in Series A warrants.
California surgical robotics maker Hansen Medical (NSDQ:HNSN) won FDA clearance for a smaller version of its Magellan catheter for use in peripheral vascular interventions.
A federal judge gives the OK on an $8.5 million settlement of a shareholders lawsuit against Hansen Medical over its 2009 financial restatement.
Hansen Medical (NSDQ:HNSN) said a federal judge approved its $8.5 million settlement of a shareholders lawsuit filed over the 2009 restatement of its financials following a fraud scandal.
A former senior vice president for Hansen Medical, Christopher Sells, must face U.S. Securities & Exchange Commission charges that he participated in a scheme to artificially inflate the robotic surgery device maker's sales figures.
A former executive with Hansen Medical (NSDQ:HNSN) can't get out of a lawsuit filed against him by the the U.S. Securities & Exchange Commission accusing him of hatching a scheme to artificially inflate Hansen's revenues.
Hansen Medical launches its re-designed Artisan study, enrolling the initial 5 patients to evaluate robot-assisted catheter surgery for atrial fibrillation.
Hansen Medical (NSDQ:HNSN) enrolled the 1st 5 patients in a re-designed study to evaluate its robot-assisted atrial fibrillation treatment.
Hansen Medical misses Wall Street's expectations during the 2nd quarter, sending shares down today on The Street.
Hansen Medical (NSDQ:HNSN) shares slipped today after the medical device company missed expectations on Wall Street with wider losses and a more than 5% sales decline.